Company Overview
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.12.
Recent Developments
- Dec 2025 Revenue of $3.57M (-86.9% YoY); net profit $-70.45M.
- Trailing 12 Months Year-on-year growth — revenue +1057.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -3.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -3.17% |
| 1 Year: | 1,057.20% |
Stock Price Performance
| 1 Year: | +26.36% |
| 6 Months: | -2.80% |
| 3 Months: | +26.94% |
| 1 Month: | +17.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -3.2% CAGR over 5 years.
- Trading 30.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACIU AC Immune SA PHARMA | 2.78 | -5.25 | $276.41M | 0.00% | -115.62% | -78.53% | -3.17% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 990.00K | 1.31M | 939.00K | 338.00K | 1.12M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 20.36M | 20.69M | 16.64M | 14.74M | 15.91M |
| Operating Income | - | -19.37M | -19.39M | -15.70M | -14.41M | -14.79M |
| EBITDA | - | -18.36M | -20.52M | -15.20M | -13.68M | -14.74M |
| Interest Expense | - | 54.00K | 50.00K | 46.00K | 42.00K | 65.00K |
| Pretax Income | - | -19.03M | -21.19M | -15.86M | -14.37M | -14.80M |
| Tax Provision | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | - | -19.03M | -21.19M | -15.86M | -14.37M | -14.80M |
| Diluted EPS | - | -0.19 | -0.21 | -0.16 | - | -0.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 3.94M | 14.80M | 27.31M | 3.57M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 74.78M | 68.42M | 79.69M | 72.44M |
| Operating Income | -70.85M | -53.62M | -52.38M | -68.86M |
| EBITDA | -68.03M | -51.83M | -48.62M | -67.75M |
| Interest Expense | 355.00K | 176.00K | 133.00K | 191.00K |
| Pretax Income | -70.74M | -54.22M | -50.91M | -70.45M |
| Tax Provision | 13.00K | 10.00K | 3.00K | 0 |
| Net Income | -70.75M | -54.23M | -50.92M | -70.45M |
| Diluted EPS | -0.85 | -0.64 | -0.51 | -0.70 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 185.94M | 182.81M | 230.91M | 154.25M |
| Current Assets | - | 128.09M | 125.15M | 171.99M | 96.72M |
| Cash & Equivalents | - | 31.59M | 78.49M | 36.27M | 26.80M |
| Inventory | - | - | - | - | - |
| Receivables | - | 0 | 14.80M | 0 | - |
| Total Liabilities | - | 16.95M | 22.17M | 118.64M | 109.37M |
| Current Liabilities | - | 11.48M | 13.58M | 100.84M | 94.69M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 2.80M | 3.50M | 5.43M | 4.54M |
| Total Equity | - | 168.99M | 160.64M | 112.27M | 44.88M |
| Shares Outstanding | - | 89.83M | 104.44M | 111.31M | 112.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -73.57M | -60.41M | 65.84M | -69.26M |
| Investing Cash Flow | - | 23.76M | 65.64M | -105.29M | 63.54M |
| Financing Cash Flow | - | -1.35M | 43.25M | -1.12M | -1.02M |
| Capital Expenditure | - | -1.24M | -801.00K | -576.00K | -900.00K |
| Free Cash Flow | - | -74.81M | -61.21M | 65.27M | -70.16M |
| Net Change in Cash | - | -51.15M | 48.49M | -40.57M | -6.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -1,800.4% | -362.3% | -191.8% | -1,927.3% |
| Net Margin % | -1,798.0% | -366.4% | -186.4% | -1,971.6% |
| ROE % | -41.9% | -33.8% | -45.4% | -157.0% |
| ROCE % | -40.6% | -31.7% | -40.3% | -115.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BVF Inc. | 19.48% | 19.82M | $52.13M |
| 2 | Wells Fargo & Company | 0.99% | 1.00M | $2.64M |
| 3 | Renaissance Technologies, LLC | 0.83% | 840.13K | $2.21M |
| 4 | Millennium Management Llc | 0.76% | 773.59K | $2.03M |
| 5 | Blackrock Inc. | 0.51% | 519.27K | $1.37M |
| 6 | Dimensional Fund Advisors LP | 0.33% | 340.08K | $894.41K |
| 7 | Arrowstreet Capital, Limited Partnership | 0.23% | 232.95K | $612.67K |
| 8 | Citadel Advisors Llc | 0.20% | 207.61K | $546.00K |
| 9 | Morgan Stanley | 0.13% | 131.81K | $346.67K |
| 10 | Two Sigma Investments, LP | 0.10% | 102.83K | $270.43K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACIU
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
ACIU — Frequently Asked Questions
What is the current share price of AC Immune SA (ACIU)?
As of 2026-09-19 21:16 PDT, AC Immune SA (ACIU) trades at $2.78 on NasdaqGM. Its 52-week range is $2.04 to $3.99.
What is the market capitalisation of ACIU?
AC Immune SA (ACIU) has a market capitalisation of $276.41M on NasdaqGM.
What is the P/E ratio of ACIU?
ACIU trades at a trailing price-to-earnings (P/E) ratio of -5.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.32.
What is the return on equity (ROE) of ACIU?
ACIU has a return on equity (ROE) of -78.53%. Its return on capital employed (ROCE) is -115.62%.
Is ACIU a good stock to buy?
This page provides a data-driven analysis of AC Immune SA (ACIU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.